Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.


a long-acting barbiturate used as the base or the sodium salt as an anticonvulsant, sedative, and hypnotic.


PMS-Phenobarbital, Solfoton

phenobarbital sodium

Luminal Sodium

Pharmacologic class: Barbiturate

Therapeutic class: Anxiolytic, anticonvulsant, sedative-hypnotic

Controlled substance schedule IV Pregnancy risk category D


Interferes with gamma-aminobutyric acid receptors, blocking nerve impulse transmission in CNS, which reduces motor activity and raises seizure threshold


Capsules: 16 mg

Elixir: 15 mg/5 ml, 20 mg/5 ml

Injection: 30 mg/ml and 60 mg/ml in 1-ml prefilled syringes; 65 mg/ml in 1-ml vials; 130 mg/ml in 1-ml prefilled syringes, 1-ml vials, and 1-ml ampules

Tablets: 15 mg, 16 mg, 30 mg, 60 mg, 90 mg, 100 mg

Indications and dosages

Tonic-clonic (grand mal) and partial seizures; febrile seizures in children

Adults: 60 to 100 mg/day P.O. as a single dose or in two or three divided doses; or initially, 100 to 320 mg I.V. p.r.n. (a total of 600 mg I.V. in a 24-hour period).

Infants and children: Loading dose of 15 to 20 mg/kg P.O. (produces drug blood level of 20 mcg/ml shortly after dosing). To achieve therapeutic blood level (10 to 25 mcg/ml), children usually need higher dosage/kg than adults. Follow loading dose with 3 to 6 mg/kg/day P.O. Alternatively, 4 to 6 mg/kg/day I.M. or I.V. for 7 to 10 days to achieve blood level of 10 to 15 mcg/ml.

Status epilepticus

Adults: 200 to 320 mg I.M. or I.V., repeated q 6 hours p.r.n.

Children: 15 to 20 mg/kg I.V. given over 10 to 15 minutes

Sedation or hypnotic effect

Adults: For sedation, 30 to 120 mg/day P.O. or 30 to 120 mg/day I.M. or I.V. in two or three divided doses. As a hypnotic, 100 to 200 mg P.O. or 100 to 320 mg I.M. or I.V. at bedtime. Don't exceed 400 mg in a 24-hour period.

Preoperative sedation

Adults: 100 to 200 mg I.M. 60 to 90 minutes before surgery

Children: 1 to 3 mg/kg I.M. or I.V., as prescribed.

Dosage adjustment

• Impaired hepatic or renal function

• Elderly or debilitated patients

Off-label uses

• Prevention and treatment of hyperbilirubinemia


• Hypersensitivity to drug or other barbiturates

• Manifest or latent porphyria

• Nephritis (with large doses)

• Severe respiratory disease with dyspnea or obstruction

• History of sedative-hypnotic abuse

• Subcutaneous or intra-arterial administration


Use cautiously in:

• hepatic dysfunction, renal impairment, seizure disorder, fever, hyperthyroidism, diabetes mellitus, severe anemia, pulmonary or cardiac disease

• history of suicide attempt or drug abuse

• chronic phenobarbital use

• elderly or debilitated patients

• pregnant or breastfeeding patients

• children younger than age 6.


• Inject I.M. deep into large muscle mass; limit volume to 5 ml.

Give I.V. no faster than 60 mg/minute. Keep resuscitation equipment at hand.

• Stop injection immediately if patient complains of pain or if circulation at injection site diminishes (indicating inadvertent intra-arterial injection).

Don't give by subcutaneous route; severe reactions (such as pain and tissue necrosis) may occur.

Know that when given I.V. for status epilepticus, drug may take 15 minutes to attain peak blood level in brain. If injected continuously until seizures stop, drug brain level would keep rising and could exceed that required to control seizures. To avoid barbiturate-induced depression, use minimal amount required and wait for anticonvulsant effect to occur before giving second dose.

• Use parenteral route only when patient can't receive drug P.O.

• Know that drug is intended only for short-term use, losing efficacy after about 2 weeks.

Adverse reactions

CNS: headache, dizziness, anxiety, depression, drowsiness, excitation, delirium, lethargy, agitation, confusion, hyperkinesia, ataxia, vertigo, nightmares, nervousness, paradoxical stimulation, abnormal thinking, hallucinations, insomnia, CNS depression

CV: hypotension, syncope, bradycardia (with I.V. use)

GI: nausea, vomiting, constipation

Hematologic: megaloblastic anemia

Hepatic: hepatic damage

Musculoskeletal: joint pain, myalgia

Respiratory: hypoventilation, laryngospasm, bronchospasm, apnea (with I.V. use); respiratory depression

Skin: rash, urticaria, exfoliative dermatitis, Stevens-Johnson syndrome

Other: phlebitis at I.V. site, drug dependence, hypersensitivity reactions including angioedema


Drug-drug. Acetaminophen: increased risk of hepatotoxicity

Activated charcoal: decreased phenobarbital absorption

Anticoagulants, beta-adrenergic blockers (except timolol), carbamazepine, clonazepam, corticosteroids, digoxin, doxorubicin, doxycycline, felodipine, fenoprofen, griseofulvin, hormonal contraceptives, metronidazole, quinidine, theophylline, verapamil: decreased efficacy of these drugs

Chloramphenicol, hydantoins, narcotics: increased or decreased effects of either drug

Cyclophosphamide: increased risk of hematologic toxicity

Divalproex, MAO inhibitors, valproic acid: decreased phenobarbital metabolism, increased sedative effect Other CNS depressants (including first-generation antihistamines, opioids, other sedative-hypnotics): additive CNS depression

Rifampin: increased phenobarbital metabolism and decreased effects

Drug-diagnostic tests. Bilirubin: decreased level in neonates and patients with seizure disorders or congenital nonhemolytic unconjugated hyperbilirubinemia

Drug-herbs. Chamomile, hops, kava, skullcap, valerian: increased CNS depression

St. John's wort: decreased drug effects

Drug-behaviors. Alcohol use: additive CNS effects

Patient monitoring

• Monitor vital signs; watch for bradycardia and hypotension.

In patients with seizure disorders, know that drug withdrawal may cause status epilepticus.

• Assess neurologic status. Institute safety measures as needed.

Closely monitor respiratory status, especially for respiratory depression and airway spasm.

• Monitor phenobarbital blood level, CBC, and kidney and liver function tests.

• Watch for signs of drug dependence.

Patient teaching

Instruct patient to promptly report rash, facial and lip edema, syncope, dyspnea, or depression.

Stress importance of taking exactly as prescribed, with or without food. Caution patient not to stop therapy abruptly, especially if he's taking drug for seizures.

• Tell patient that prolonged use may lead to dependence.

• Instruct patient to seek medical advice before taking other prescription or over-the-counter drugs.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects him.

• Advise patient to avoid herbs, alcohol, and other CNS depressants.

• Instruct patient taking hormonal contraceptives to use alternate birth-control method.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.


A long-acting oral or parenteral sedative, anticonvulsant, and hypnotic; also available as a soluble sodium salt; also used in therapeutic management of epilepsy and induction of hepatic microsomal enzymes.


(fē′nō-bär′bĭ-tôl′, -tăl′)
A long-acting barbiturate, C12H12N2O3, used medicinally as a sedative, hypnotic, and anticonvulsant, sometimes in the form of its sodium salt.


Neurology A long-acting barbiturate used as a hypnotic, sedative, hepatic enzyme inducer, anticonvulsant, given as a monotherapy for partial seizures, 2º generalized seizures; also used to treat diarrhea and to ↑ the antitumor effect of other therapies. See Seizures, Therapeutic drug.


(Pb, PB) (fē'nō-bahr'bi-tahl)
A long-acting oral or parenteral sedative, anticonvulsant, and hypnotic.
Synonym(s): phenylethylbarbituric acid, phenylethylmalonylurea.


A long-acting oral or parenteral sedative, anticonvulsant, and hypnotic.

Patient discussion about phenobarbital

Q. What are the Brands of Sodium-phenobarbitone drug in Bangladesh?

A. maybe this link will help-

if not- i recommend asking an Indian pharmacist..

More discussions about phenobarbital
References in periodicals archive ?
In studies conducted in our country, phenobarbital intoxications constituted less than 1% of cases presenting to pediatric emergency deparments (1).
Phenobarbital is believed to exert a neuroprotective effect partially by reducing brain metabolism and oxygen intake.
Figure 3 shows the effects of montelukast (10 mg/kg, sc) and phenobarbital (20 mg/kg, sc) on PTZ-induced seizures (35 mg/kg, ip), measured as the latency to myoclonic jerk (A) and latency to generalized tonic-clonic seizures (B).
Although the upregulation of the GABA-A receptors plays a vital role for the emergence of the effects of phenobarbital and primidone, these agents may also act through the inhibition of sodium, potassium, and calcium ion channels.
[9.] Kjaer D, Horvath-Puho E, Christensen J, Vestergaard M, Czeizel AE, Sorensen HT,Olsen J: Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: a case-time-control study.
Predisposing Drugs Antituberculosis agents: Isoniazid Pyrazinamide Antiepileptic drugs: Hydantoins Ethionamide Phenobarbital Diazepam Chemotherapy and immunosuppressive drugs 6-Mercaptopurine 5-Fluorouracil Chlorambucil Azathioprine Chloramphenicol
Of the 21 patients in the placebo group who had seizures, 6 continued to have seizures despite administration of phenytoin and clonazepam and were subsequently treated with phenobarbital after the code was broken.
During initial treatment, one might use a chlordiazepoxide or phenobarbital taper and use lorazepam for breakthrough anxiety and/or panic until symptoms are stable.
phenobarbital, induced substantial regionally specific cell death, In vitro study [10] has demonstrated that the secretion of testicular testestrone is in response to the stimulatory action of gonadotrophins.
A single bottle of hydrocodone bitartrate and acetaminophen tablets was incorrectly labeled as phenobarbital. As a result, the company is recalling the following products:
The individual anti-epileptic drugs studied included carbamazepine, clonazepam, ethosuximide, gabapentin, phenobarbital, phenytoin and valproic acid.
Other commonly used drugs, such as carbamazepine, phenobarbital, lamotrigine, and phenytoin are currently being evaluated in the same study.